Inozyme Pharma (INZY) News Today $4.00 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INZY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Inozyme Pharma Inc News (INZY) - Investing.comJuly 2 at 10:36 AM | investing.comBioMarin Announces Completion of Acquisition of InozymeJuly 1 at 8:45 AM | prnewswire.comInozyme Pharma Inc Ordinary SharesJune 21, 2025 | morningstar.comMInozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersJune 20, 2025 | globenewswire.comInozyme Pharma Reports Increased Loss Amid Strategic FocusJune 9, 2025 | tipranks.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Hold" from BrokeragesJune 9, 2025 | marketbeat.comMillennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)May 30, 2025 | marketbeat.comBMRN to Acquire Inozyme PharmaMay 22, 2025 | finance.yahoo.comINOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYMay 21, 2025 | businesswire.comJacobs Levy Equity Management Inc. Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY)May 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Acquires New Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)May 20, 2025 | marketbeat.com443,255 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Acquired by SanofiMay 19, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Needham & Company LLCMay 19, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Downgraded to "Hold" Rating by WedbushMay 19, 2025 | marketbeat.comJefferies Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comNeedham Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comLeerink bullish on BioMarin following Inozyme deal, expects additional BDMay 17, 2025 | finance.yahoo.comInozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by BrokeragesMay 17, 2025 | marketbeat.comInozyme Shares More Than Double in Surge Toward BioMarin's Buyout PriceMay 16, 2025 | marketwatch.comBioMarin stock rises following Inozyme Pharma acquisitionMay 16, 2025 | in.investing.comBioMarin to buy enzyme therapy developer Inozyme in $270M all-cash dealMay 16, 2025 | msn.comInozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment BrightensMay 16, 2025 | msn.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZYMay 16, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of ShareholdersMay 16, 2025 | prnewswire.comINZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to ShareholdersMay 16, 2025 | businesswire.comShareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public ShareholdersMay 16, 2025 | businesswire.comBioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme PharmaMay 16, 2025 | prnewswire.comInozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | finance.yahoo.comInozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business HighlightsMay 14, 2025 | globenewswire.comRenaissance Technologies LLC Buys 256,599 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)May 2, 2025 | marketbeat.comInozyme Pharma (INZY) to Release Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Has $14.29 Million Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY)April 30, 2025 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of "Buy" from BrokeragesApril 21, 2025 | marketbeat.comAffinity Asset Advisors LLC Raises Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)April 17, 2025 | marketbeat.comInozyme announces JBMR Plus publication on ENPP1 deficiencyApril 11, 2025 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Given Buy Rating at Needham & Company LLCApril 10, 2025 | marketbeat.comInozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 DeficiencyApril 10, 2025 | globenewswire.comInozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 DeficiencyApril 10, 2025 | globenewswire.comInozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comInozyme Pharma (INZY) Gets a Buy from Bank of America SecuritiesMarch 17, 2025 | markets.businessinsider.comHC Wainwright Boosts Earnings Estimates for Inozyme PharmaMarch 15, 2025 | marketbeat.comQ1 EPS Estimates for Inozyme Pharma Decreased by AnalystMarch 14, 2025 | marketbeat.comQ1 Earnings Estimate for Inozyme Pharma Issued By WedbushMarch 14, 2025 | marketbeat.comRaymond James Cuts Inozyme Pharma (NASDAQ:INZY) Price Target to $12.00March 13, 2025 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Given New $23.00 Price Target at Piper SandlerMarch 12, 2025 | marketbeat.comInozyme price target lowered to $12 from $24 at Raymond JamesMarch 12, 2025 | markets.businessinsider.comInozyme Pharma (NASDAQ:INZY) Price Target Cut to $15.00 by Analysts at Needham & Company LLCMarch 12, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Inozyme Pharma (NASDAQ:INZY)March 12, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY)March 11, 2025 | marketbeat.comInozyme Pharma Focuses on ENPP1 Deficiency ProgramMarch 10, 2025 | tipranks.com Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Media Mentions By Week INZY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼0.470.90▲Average Medical News Sentiment INZY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼42▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enliven Therapeutics News Verve Therapeutics News Intellia Therapeutics News Collegium Pharmaceutical News Akebia Therapeutics News Spyre Therapeutics News Mineralys Therapeutics News Avadel Pharmaceuticals News Pharvaris News Nurix Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INZY Stock Alerts